Optimi Health (TSE:OPTI) has released an update.
Optimi Health Corp. and Psyence Biomedical Ltd. have announced their intention to partner, with Optimi set to become the exclusive supplier of GMP nature-derived psilocybin extract for Psyence’s FDA-approved palliative care therapies. The collaboration aims to support Psyence’s clinical trials and regulatory submissions in advancing psilocybin-based mental health treatments. While the letter of intent is non-binding, the successful execution of a binding agreement could lead to transformative treatments within the palliative care sector.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
